CClinicalTrials.gg
Sign In
CompletedNCT02323672Updated Feb 10, 2017

Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions

An observational study in Precancerous Conditions and Oral Cancer, sponsored by Cairo University. Completed. Open to participants aged 40 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-10.

Sponsored by Cairo University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
45
Ages
40 Years to 50 Years
Sex
All
01

Study summary

45 individuals were subdivided into 3 groups, 15 patients with oral premalignant lesions, 15 patients with oral malignant lesions and 15 control individuals. Levels of chemerin and MMP-9 were evaluated in serum and saliva of these subjects utilizing the ELISA technique.

Read the detailed description

45 individuals were subdivided into 3 groups, 15 patients suffering from oral premalignant lesions, 15 patients suffering from oral malignant lesions and 15 individuals having age, gender and periodontal status matched with both patients groups acting as a control group. Serum and whole unstimulated saliva samples were collected from all the included groups in order to determine chemerin and MMP-9 in serum and saliva utilizing the ELISA technique.

02

Conditions studied

  • Precancerous Conditions
  • Oral Cancer
03

In context

Mouth Neoplasms

377 studies on the registry are indexed under Mouth Neoplasms; 126 are open to participants now.

This study's enrollment of 45 is below the median of 90 across 103 observational studies indexed under Mouth Neoplasms.

Browse Mouth Neoplasms studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

45 individuals were subdivided into 3 groups, 15 patients suffering from oral squamous cell carcinoma lesions, 15 patients suffering from oral premalignant lesions (OPL) and 15 individuals having age, gender and periodontal status matched with both patients groups acting as a control group.

Inclusion criteria

  • patients with oral premalignant lesions.
  • patients with oral malignant lesions.

Exclusion criteria

Exclusion Criteria:

  • any systemic disease other than oral premalignant or malignant lesions. smokers. pregnant females. periodontal diseases.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
45 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • oral premalignant patients

    15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia.

  • oral malignant patients

    15 patients suffering from oral malignant lesions

  • control subjects

    15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease.

06

What researchers measure

Primary outcomes

  1. salivary levels of chemerin in patients with oral premalignant and malignant lesions.

    Time frame: 1 day

Secondary outcomes

  1. serum levels of chemerin in patients with oral premalignant and malignant lesions.

    Time frame: 1 day

  2. serum levels of MMP-9 in patients with oral premalignant and malignant lesions.

    Time frame: morning visit

  3. salivary levels of MMP-9 in patients with oral premalignant and malignant lesions.

    Time frame: 1 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Skrzeczynska-Moncznik J, Stefanska A, Zabel BA, Kapinska-Mrowiecka M, Butcher EC, Cichy J. Chemerin and the recruitment of NK cells to diseased skin. Acta Biochim Pol. 2009;56(2):355-60. Epub 2009 Jun 18. PubMed 19543554 ↗
  • Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M, Tabellini G, Moretta A, Sozzani S. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 2007 May 1;109(9):3625-32. doi: 10.1182/blood-2006-08-038844. Epub 2007 Jan 3. PubMed 17202316 ↗
  • Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol. 2001 Feb;28(2):72-82. doi: 10.1034/j.1600-0560.2001.280203.x. PubMed 11168755 ↗
  • Nanda DP, Dutta K, Ganguly KK, Hajra S, Mandal SS, Biswas J, Sinha D. MMP-9 as a potential biomarker for carcinoma of oral cavity: a study in eastern India. Neoplasma. 2014;61(6):747-57. doi: 10.4149/neo_2014_091. PubMed 25150320 ↗
  • Wang N, Wang QJ, Feng YY, Shang W, Cai M. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin Oral Investig. 2014 Apr;18(3):997-1004. doi: 10.1007/s00784-013-1046-8. Epub 2013 Jul 19. PubMed 23868294 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02323672
Lead sponsor
Cairo University
Responsible party
Noha Ayman Ghallab (Associate Professor of periodontology and Oral Medicine, faculty of oral and dental medicine, Cairo University) — Principal investigator
First posted
Dec 23, 2014
Start date
Feb 2014
Primary completion
Sep 2014
Completion
Oct 2014
Last update
Feb 10, 2017

Study contacts

Noha Ghallab, M.D.
principal investigator · Associate Professor of periodontology and Oral Medicine faulty of oral and dental medicine Cairo Unv.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Mouth Neoplasms→

Other studies from this sponsor

Cairo University

Start the discussion